Yinong Xie, based in California, United States, is currently a CEO at SYNBLic Therapeutics, Inc., bringing experience from previous roles at Sichuan Kelun Pharmaceutical Co., Ltd., Eli Lilly and Company, BioDuro, a PPD Company and Exelixis, Inc.. Yinong Xie holds a 2001 - 2003 Postdoctoral Fellow in under Prof. K. Barry Sharpless @ Scripps Research. With a robust skill set that includes Leadership, Development, Research, Strategic Planning, Chemistry and more, Yinong Xie contributes valuable insights to the industry. Yinong Xie has 2 emails on RocketReach.